Ittrium (90y) Kolloid Cis Bio International (Yttrium (90y) Citrate)

Yttrium-90 citrate emits beta particles that penetrate the synovial lining, causing selective cellular damage and fibrosis. This ablates inflamed synovial tissue, reduces inflammatory mediator production, and limits joint effusion, leading to pain relief and improved function.

The dose of Ittrium is determined by the prescribing physician based on joint size, disease severity and individual patient factors. The product is supplied as a sterile injectable solution, and the exact activity to be administered is set by the treating specialist.

Safety of Yttrium-90 citrate in pregnancy or lactation has not been established. Because the product delivers localized radiation, it is generally avoided in pregnant or nursing patients unless the potential benefit outweighs the potential risk, as assessed by the clinician.

To order Ittrium, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Ittrium (Yttrium-90 citrate) delivers beta radiation with a relatively short tissue penetration depth, making it suitable for medium‑sized joints. Compared with alternatives such as Phosphorus‑32 or Rhenium‑186, Yttrium‑90 provides a higher energy beta emission, allowing effective synovial ablation while limiting exposure to surrounding structures.

Ittrium should be stored at 2‑8 °C in its original shielded vial, protected from light and never frozen. The product must be handled by trained personnel using appropriate radiation safety measures, and any unused portion should be returned to the supplier or disposed of according to local radiopharmacy regulations.

Ittrium is administered by a qualified healthcare professional as an intra‑articular injection. The joint is first aspirated to remove excess fluid, then the calculated activity of the Yttrium‑90 citrate solution is injected under sterile conditions, followed by post‑procedure monitoring.

Serious risks include radiation‑induced cartilage or bone damage, deep tissue necrosis, severe joint infection, systemic radiation exposure leading to hematologic changes, and rare hypersensitivity reactions. Patients should be monitored closely for signs of these complications after the procedure.

Ittrium is contraindicated in patients with active joint infection, uncontrolled bleeding disorders, known hypersensitivity to the citrate carrier, or in pregnant and lactating women unless the benefit justifies the risk. Clinicians should also avoid use in patients receiving high‑dose systemic radiation or chemotherapy.